Filing Flows › Teva Pharmaceutical Industries (TEVA) › Next earnings date
Teva Pharmaceutical Industries (TEVA) earnings: beat the estimate
Teva Pharmaceutical Industries (TEVA) reported on Nov 3, 2026 and beat the EPS estimate: $0.86 against $0.72 (+19.3%). Revenue was $4.4B for Q3 2026, -2% year over year. It beat the EPS estimate in 100% of the quarters on record.
The last report
Teva Pharmaceutical Industries reported revenue of $4.4B for the third quarter 2026 (-2% Y/Y), net earnings $234M: Sale of goods $3.7B, Distribution $421M, Other $184M, Licensing arrangements $49.0M. How it makes money → · Every quarter →
Teva Pharmaceutical Industries' latest quarter
Teva Pharmaceutical Industries, Q3 2026: revenue $4.4B (-2% year over year), operating margin 16.2%, net earnings $234M, operating cash flow $241M. The chart follows the revenue to costs, profit and cash.
Questions
Did Teva Pharmaceutical Industries beat earnings?
Teva Pharmaceutical Industries (TEVA) reported on Nov 3, 2026 and beat the EPS estimate: $0.86 against $0.72 (+19.3%).
When does TEVA report earnings?
The next date is not set yet.
Does Teva Pharmaceutical Industries usually beat earnings?
It beat the consensus EPS estimate in 100% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.